A review of the benefit–risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.22, Iss.3, 2006-03, pp. : 561-573

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

Oncology, Vol. 79, Iss. 5-6, 2011-04 ,pp. : 423-429

Karger

Access to resources Recommend Favorite

Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras

Oncology, Vol. 76, Iss. 4, 2009-02 ,pp. : 239-246

Karger

Access to resources Recommend Favorite

Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 509-513

Karger

Access to resources Recommend Favorite

Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib

Oncology, Vol. 79, Iss. 5-6, 2011-03 ,pp. : 355-362

Karger

Access to resources Recommend Favorite

Evaluation of the Efficacy and Safety of the Combination of Gemcitabine and Nedaplatin for Elderly Patients with Advanced Non-Small-Cell Lung Cancer

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 273-280

Karger

Access to resources Recommend Favorite